Biotech entity
Every one of those 1 sits in a single category, pharma. Cibus Inc is most often covered alongside Haduvio, which appears in 1 of these 1 story. Cibus Inc appears in 1 tracked Biotech story from March 18, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 18, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Cibus Inc is most often covered alongside Haduvio, which appears in 1 of these 1 story. Cibus Inc appears in 1 tracked Biotech story from March 18, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cibus Inc. Shared-story counts are live from our verified record — not editorial picks.
Trevi Therapeutics and Cibus Inc reported Q4 2025 results, highlighting a divergence in fiscal health as Trevi outperformed earnings expectations while Cibus faced mounting financial pressure. Both companies remain focused on high-stakes technical milestones, with Trevi advancing its lead asset Haduvio and Cibus pushing gene-edited crop traits toward commercialization.
Cibus Inc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
